Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-28T03:33:29.603Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparative Effects of Lithium and Chlorpromazine in the Treatment of Acute Manic States

Published online by Cambridge University Press:  29 January 2018

Gordon Johnson ,
Samuel Gershon ,
Eugene I. Burdock ,
Arthur Floyd  and
Leon Hekimian
Gordon Johnson
Affiliation:
Neuropsychopharmacology Research Unit
Samuel Gershon
Affiliation:
Neuropsychopharmacology Research Unit
Eugene I. Burdock
Affiliation:
Neuropsychopharmacology Research Unit, Department of Psychiatry, New York University Medical Center, 550 First Avenue, New York, U.S.A.
Arthur Floyd
Affiliation:
Neuropsychopharmacology Research Unit, Department of Psychiatry, New York University Medical Center, 550 First Avenue, New York, U.S.A.
Leon Hekimian
Affiliation:
Neuropsychopharmacology Research Unit, Department of Psychiatry, New York University Medical Center, 550 First Avenue, New York, U.S.A.
Get access Rights & Permissions [Opens in a new window]

Extract

There are well over 50 published reports since 1949 on the use of lithium salts in psychiatric disorders, most of them in the decade since 1960. Considering only those studies reported in acute manic states, it is difficult to arrive at a reliable assessment of the specific therapeutic effect of lithium because quantitative evaluations were seldom employed, so that comparisons of outcome have to be based on statements of degree of improvement which are subject to varying interpretations. Furthermore most of the studies were not adequately controlled, and the diagnostic criteria used were not always clear.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 119 , Issue 550 , September 1971 , pp. 267 - 276
Copyright
Copyright © The Royal College of Psychiatrists, 1971 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Baldessarini, R., and Stephens, J. (1970). ‘Lithium Carbonate for Affective Disorders.’ Archives of General Psychiatry, 22, 72–7.CrossRefGoogle ScholarPubMed
2. Bunney, W. E., Goodwin, F. R., Davis, J. M., and Fawcett, J. A. (1968). ‘A Behavioural-bio-chemical Study of lithium treatment.’ American Journal of Psychiatry, 125, 499–512.CrossRefGoogle ScholarPubMed
3. Burdock, E. I., and Hardesty, A. S. (1969). ‘A research tactic for evaluation of drug specificity in schizophrenia.’ In Siva Sankar, D. V. (Ed.), Schizophrenia: Current Concepts and Research. N. Y.: PJD Publications, Pp. 174–81.Google Scholar
4. Burdock, E. I., and Hardesty, A. S. (1969). Structural Clinical Interview Manual. N.Y.: Springer Publishing Co.CrossRefGoogle Scholar
5. Friedhoff, A. J., and Hekimian, L. H. (1964). ‘Clinical case report forms.’ Journal of New Drugs, 4, 209–12.Google Scholar
6. Greenspan, K., Green, R., and Durell, J. (1968). ‘Retention and distribution patterns of lithium, a pharmacological tool in studying the pathophysiology of manic-depressive psychosis.’ American Journal of Psychiatry, 125, 512–9.CrossRefGoogle ScholarPubMed
7. Hekimian, L., Gershon, S., Burdock, E. I., and Hardesty, A. S. (1969). ‘Drug efficacy and diagnostic specificity in manic depressive illness and schizophrenia.’ Diseases of the Nervous System, 11, 747–52.Google Scholar
8. Johnson, G., Gershon, S., and Hekimian, L. J. (1968). ‘Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: An interim report.’ Comprehensive Psychiatry, 9, 563–73.Google Scholar
9. Johnson, G., Gershon, S., Maccarrio, M., Gershon, S., and Korein, J. (1969). ‘The effects of lithium on EEG, behaviour, and serum electrolytes.’ Journal of Nervous and Mental Disease, 151, 273–89.Google Scholar
10. Johnson, G., Gershon, S., Maccarrio, M., Gershon, S., and Korein, J. (1970). ‘Differential response to lithium carbonate in manic depressive and schizoaffective disorders.’ Diseases of the Nervous System, 9, 613–15.Google Scholar
11. Maggs, R. (1963). ‘Treatment of manic illness with lithium carbonate.’ British Journal of Psychiatry, 109, 56–65.Google Scholar
12. Penrose, L. S. (1954). ‘Distance, size and shape.’ Annals of Eugenics, 18, 377–43.Google Scholar
13. Rochford, J. M., Detre, T., Tucker, G., and Harrow, M. (1970). ‘Neuropsychological impairment in functional psychiatric diseases.’ Archives of General Psychiatry, 22, 114–9.Google Scholar
14. Schou, M., Juel-Nielson, N., Stromgren, E., and Voldby, H. (1954). ‘The treatment of manic psychoses by the administration of lithium salts.’ Journal of Neurology, Neurosurgery and Psychiatry, 17, 250–60.Google Scholar
15. Spring, G., Schweid, D., Gray, C., Steinberg, J., Hartwitz, M. (1970). ‘A double-blind comparison of lithium and chlorpromazine in the treatment of manic states’ American Journal of Psychiatry, 126, 1306–09.Google Scholar
16. Trautner, E. M., Morris, R., Noack, C. H. and Gershon, S. (1955). ‘The excretion and retention of ingested lithium and its effect on the ionic balance of man.’ Medical Journal of Australia, 2, 280–91.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.